Focus

The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation

Quality Improvement Guidelines for Transhepatic Arterial Chemoembolization, Embolization, and Chemotherapeutic Infusion for Hepatic Malignancy

Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)?

Chemoembolization and Radioembolization for Hepatocellular Carcinoma

Treatment for Hepatocellular Carcinoma in South Asia

New Developments in the Treatment of Hepatocellular Carcinoma: The Concept of Adjuvant and Neoadjuvant Chemotherapy

Hepatocellular Carcinoma Radiation Therapy: Review of Evidence and Future Opportunities

Society of Interventional Radiology Position Statement on Chemoembolization of Hepatic Malignancies

Vascular Dysfunction in Heart Failure with Preserved Ejection Fraction

Sorafenib is the only standard treatment for unresectable hepatocellular carcinoma (HCC), but it provides modest survival benefits over placebo, necessitating predictive biomarkers of the response to sorafenib. Serum samples were obtained from 115 consecutive patients with HCC before sorafenib treatment and analyzed by multiple reaction monitoring-mass spectrometry (MRM-MS) and ELISA to quantify candidate biomarkers. We verified a triple-marker panel to be predictive of the response to sorafenib by MRM-MS, comprising CD5 antigen-like (CD5L), immunoglobulin J (IGJ), and galectin-3-binding protein (LGALS3BP), in HCC patients. This panel was a significant predictor (AUROC > 0.950) of the response to sorafenib treatment, having the best cut-off value (0.4) by multivariate analysis. In the training set, patients who exceeded this cut-off value had significantly better overall survival (median, 21.4 months) than those with lower values (median, 8.6 months; p = 0.001). Further, a value that was lower than this cutoff was an independent predictor of poor overall survival [hazard ratio (HR), 2.728; 95% confidence interval (CI), 1.312-5.672; p = 0.007] and remained an independent predictive factor of rapid progression (HR, 2.631; 95% CI, 1.448-4.780; p = 0.002). When applied to the independent validation set, levels of the cut-off value for triple-marker panel maintained their prognostic value for poor clinical outcomes. On the contrast, the triple-marker panel was not a prognostic factor for patients who were treated with transarterial chemoembolization (TACE). The discriminatory signature of a triple-marker panel provides new insights into targeted proteomic biomarkers for individualized sorafenib therapy.

The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications

Liver cancer: Approaching a personalized care

miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo

Staging for Hepatocellular Carcinoma: Complex and Confusing

Rethinking future development of molecular therapies in hepatocellular carcinoma: A bottom-up approach